Frank Karbe

Director of Phathom Pharmaceuticals

As of Nov 9, 2026: Frank Karbe (Director, PHAT) reported no shares bought or sold themselves in the last 12 months (Form 4). PHAT's Quality Score is -4. Scores as of 9:50 AM ET, 15 minutes behind.

No shares they bought or sold themselves in the last 12 months. Their newest Form 4, for May 19: stock award (24,122 PHAT shares).

Bought$012 months Sold$012 months Last filedMay 19stock award

From SEC Form 4s · Insiders have 2 business days to file a trade

Every trade Frank Karbe reported

None in the last 12 months, as filed.

Every Form 4 Frank Karbe filed, as filed, on EDGAR

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See PHAT's 14 chart checksSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

Frank Karbe's companies

Where Frank Karbe files, with the stock's Quality Score

Stock	Title, as filed	Trades	Quality Score
PHATPhathom PharmaceuticalsDirector	Directortitle as of May 21	0	-4

Alerts for Frank Karbe

An email for each Form 4 Frank Karbe files, with the stock's Quality Score.

Set an alert

A free account. No card.

Use this page

Kept by Andrew Gomes, Breakaway's founder, from the SEC's Form 4 filings. Updated May 19, 2026.

Their filings on the SEC's site

Free to reuse with a link to this page.

How to cite

Breakaway, Frank Karbe: Director at Phathom Pharmaceuticals (PHAT), May 19, 2026, getbreakaway.com/insiders/frank-karbe

Journalists: email support@getbreakaway.com for the data behind this page.

Others who file at Phathom Pharmaceuticals

Insider trades by person

Frank Karbe

Every trade Frank Karbe reported

Frank Karbe's companies

Use this page

Others who file at Phathom Pharmaceuticals

Every insider trade, with its stock's score.